{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:28:32Z","timestamp":1761092912330,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.urolonc.2008.10.027","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T05:23:20Z","timestamp":1241501000000},"page":"322-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?"],"prefix":"10.1016","volume":"27","author":[{"given":"J. Alfred","family":"Witjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2007","series-title":"Guidelines for the management of non-muscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update","key":"10.1016\/j.urolonc.2008.10.027_bib1"},{"year":"2008","series-title":"Update March 2008","author":"Babjuk","key":"10.1016\/j.urolonc.2008.10.027_bib2"},{"key":"10.1016\/j.urolonc.2008.10.027_bib3","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A combined analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.10.027_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib6","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","author":"Lerner","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","article-title":"Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: Toxicity and marker response","volume":"176","author":"van der Heijden","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine: A phase 1 and pharmacokinetic study","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib12","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomized controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","article-title":"Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy vs. chemotherapy alone for superficial bladder cancer","volume":"155","author":"Colombo","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib15","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.027_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"Suppl 150","key":"10.1016\/j.urolonc.2008.10.027_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1569-9056(07)60149-3","article-title":"Intravesical hyperthermia and MMC for (BCG refractory) CIS of the urinary bladder","volume":"6","author":"Witjes","year":"2007","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908003219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908003219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:55:53Z","timestamp":1761040553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143908003219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1078143908003219"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.10.027","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}